FDA Warning Letter
An FDA Warning Letter is a formal communication in which the U.S. Food and Drug Administration notifies a company of violations the agency considers significant, and requests prompt correction and a written response.
What is an FDA Warning Letter?
A Warning Letter is the FDA's principal means of formally notifying a firm that the agency has found significant violations of the laws and regulations it administers — for device companies, most often quality system failures, unapproved marketing claims, or reporting violations. Warning Letters are published on the FDA's Warning Letters page, which makes them visible to customers, investors and competitors as well as to the recipient.
How does a Warning Letter differ from a Form 483?
An FDA Form 483 lists an investigator's observations at the end of an inspection; it is not a final agency determination. A Warning Letter is an agency-level compliance action, typically issued after the FDA has reviewed the inspection record and any firm response and concluded that violations are significant. Not every 483 leads to a Warning Letter, and a strong, well-documented response to the 483 is the main opportunity to prevent escalation.
How should a company respond to a Warning Letter?
The letter states a response deadline — commonly 15 working days. Effective responses acknowledge the findings, present a systemic corrective plan rather than isolated fixes, include objective evidence of completed actions, and give realistic timelines for the remainder. The FDA evaluates the response and may follow up with a re-inspection; it closes the matter with a close-out letter only after verifying that corrections are complete.
What happens if violations are not corrected?
Escalation options include import alerts and refusal of admission for foreign manufacturers, seizure, injunction, and civil money penalties. For device firms, an unresolved Warning Letter can also block clearance of certain premarket submissions and disqualify the firm from certificates to foreign governments, which directly affects registrations in other markets.
Foreign manufacturers selling into the United States receive Warning Letters too — commonly after foreign establishment inspections or reviews of imported product.
Market · Jul 24, 2026FDA US Medical Device RegistrationBlog · Aug 10, 2026Surgical Robots: Eight Markets, Eight Regulatory FilesRegulatory Update · Aug 9, 2026FDA FY 2027 Medical Device User FeesBlog · Aug 3, 2026ISO 10993-1:2025: One Core, Seven Regulatory SystemsBlog · Jul 27, 2026IVD Global Market Access 2026Blog · Jul 20, 2026Orthopedic Implants: The 2026 Global Market-Access MapRegulatory Update · Jun 2, 2026FDA Human Factors Guidance 2026 Update for Device SubmissionsRegulatory Update · Apr 30, 2026CMS and FDA RAPID Coverage Pathway 2026 for Breakthrough Medical DevicesRegulatory Update · Apr 8, 2026FDA 2026 Guidance on Voluntary Patient Preference InformationVideo · Mar 12, 2026How to Register a Medical Device with the US FDALet's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us